Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $37,563.20 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the sale, the insider now owns 2,507 shares in the company, valued at approximately $346,216.70. This trade represents a 9.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.00, for a total value of $147,285.00.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $138.10 on Monday. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The stock’s fifty day moving average is $128.11 and its 200-day moving average is $130.81. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 37.02 and a beta of 0.33.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NBIX shares. Piper Sandler reiterated an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $166.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Plato Investment Management Ltd lifted its holdings in shares of Neurocrine Biosciences by 2,481.9% in the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after buying an additional 10,548 shares during the period. Swiss National Bank boosted its position in shares of Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $3,236,000. KBC Group NV raised its holdings in shares of Neurocrine Biosciences by 78.3% in the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Neurocrine Biosciences by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock valued at $2,238,000 after purchasing an additional 7,597 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.